Simplivia Healthcare Ltd.

www.simplivia.com

Formerly Tevadaptor, Migada

High-Tech Company

TECH VERTICALS

Drug Delivery, Healthtech, Life Sciences, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	Revenue Growth
Established	2019
Number of Employees	55
Reg. Number:	abCDe

DESCRIPTION

Simplivia Healthcare is dedicated to developing and manufacturing innovative medical solutions for drug delivery to ensure the safety of healthcare professionals, including pharmacists, nurses, and veterinarians. The company’s leading closed system transfer devices (CSTD) protect against exposure to hazardous drugs during drug preparation and administration. Simplivia’s advanced Tevadaptor® product family includes a complete portfolio for any drug handling protocol, and incorporates patented Toxi-Guard® double-membrane air-cleaning technology® for safety at the highest standards when handling hazardous drugs. The company's next-generation Chemfort™ product line incorporates all of Tevadaptor®’s advantages, as well as upgraded materials, improved convenience and user experience, and suitability for an expanded range of medicines.

TECHNOLOGY

Closed System transfer devices for drug delivery.

Products and Phases

Product	Phase
Chemfort™	FDA Approved CE Approved
Chemfort™ is a closed system transfer device (CSTD) that incorporates all of Tevadaptor®’s demonstrated advantages while offering upgraded materials and improved usability. Chemfort™ has been scientifically proven to keep healthcare professionals safe when handling hazardous drugs. Chemfort™ includes a complete portfolio of products for any handling protocol.
ToxiGuard®	FDA Approved CE Approved
ToxiGuard drug-binding matrix mechanical barrier.
Tevadaptor®	FDA Approved CE Approved
Tevadaptor® is a closed system transfer device (CSTD) cleared by the FDA under the ONB product code and CE approved. Meeting the NIOSH definitions for CSTDs, Tevadaptor®’s patented Toxi-Guard® double membrane air-cleaning technology® provides safety at the highest standards when handling hazardous drugs. Tevadaptor® includes a complete portfolio of products for any handling protocol.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Hospitals and Healthcare professionals, including pharmacists, nurses, and veterinarians.

	BUSINESS MODEL
	B2B

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
		Israel Corp.
	Spin-off	Kenon Holdings Ltd.	Israel Corp.
B74752FC-1F7A-E111-AC59-00155D32A403	Subsidiary	Teva Pharmaceutical Industries Ltd.	Israel Corp.
08DAFA71-62CF-F011-B81B-00505695CD29	Accelerator	Teva Rise	Teva Pharmaceutical Industries Ltd.
31149D67-99DA-E811-80F8-0050569A1018	Spin-off	89bio Ltd.	Teva Pharmaceutical Industries Ltd.	Acquired/Merged
92EA7F36-ACCF-E811-80F7-0050569A1018	Spin-off	Seegnal eHealth Ltd.	Teva Pharmaceutical Industries Ltd.
FAE69F5A-0A2E-E911-80FD-0050569A1018	Spin-off	Simplivia Healthcare Ltd.	Teva Pharmaceutical Industries Ltd.

CONTACT INFO

Expand / Collapse All

Main Address: Kiryat Shmona, Israel

Address	1 Eli Horvitz St., Industrial Area South
POB	888
City	Kiryat Shmona
Country	Israel
Zip	1101801

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. David Delouya	CEO
Mr. Itsik Shmueli	VP, Operations
Mr. Dima Rainer	CCO & VP, Sales

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Owner, Frutarom
abC Defghij	Board Member	Senior Partner, FIMI
abC Defghij	Board Member	CEO & Co-Founder, Innoging Medical

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Acquired

Feb. 10, 2019

Revenue Growth

abCDe

NIS 170

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Private Equity Fund	abCDe	10/2020: Sold 33% of the company to The Phoenix Holdings and Leumi Partners, in equal shares, for $47 million. Holds 65% of the company.
abC Defghij	Private Investor	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Secondary Deal

Oct. 25, 2020

Revenue Growth

abCDe

FIMI sold 33% of the company to The Phoenix Holdings and Leumi Partners, in equal shares.

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Institutional Investor	abCDe	Purchased 16.5% of the company from FIMI.
abC Defghij	Investment Company	abCDe	Purchased 16.5% of the company from FIMI.

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Mar. 01, 2022

Revenue Growth

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

	Acquisitions made by Simplivia

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	Jan. 05, 2021	abCDe	The deal amount may increase to $9.35m, based on milestones.

Last Updated:	abCDe
IVC Number:	abCDe